Navigation Links
Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA
Date:6/27/2011

ard-looking statements, which statements are indicated by the words "may," "will," "plans," "intends, " "believes," "expects," "anticipates," "potential," "could," "would," "should," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the outcome of further analyses of the clinical data generated during the PREGNANT Study by the FDA; success in obtaining timely approval of PROCHIEVE in the preterm birth indication by the FDA; the impact of competitive products and pricing; the timing and level of success of a future product launch, if any; the ability of Columbia's third-party manufacturers to supply PROCHIEVE; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations, including Medicaid; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; the ability to obtain and enforce patents and other intellectual property rights; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's and Watson's reports filed with the SEC, including, but not limited to, their respective Annual Reports on Form 10-K for the year ended December 31, 2010 and Quarterly Report on Form 10-Q for the period ended March 31, 2011. Neither Columbia nor Watson undertake any responsibility to revise or update any forward-looking statements contained herein, except as ex
'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
3. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
4. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
5. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
6. HealthWarehouse.com Partners with Columbia Medical Associates to Bring Affordable Healthcare to Washington State
7. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
8. Columbia Laboratories to Discuss Fourth Quarter and Year End 2010 Financial Results on March 10, 2011, Conference Call
9. Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
10. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... five studies sponsored,by Ortho Biotech Products, L.P. will ... Spring Clinical Meetings from April 2 - 6, ... The data include studies that compare drug utilization ... (DARB), evaluate medical costs,related to chronic kidney disease ...
... FOSRENOL(R) and Resources ... Enhanced Hyperphosphatemia Management, PHILADELPHIA, April 3, 2008 ... of On Track,an innovative program designed to improve adherence ... 5 patients with,hyperphosphatemia (elevated levels of phosphorus in the ...
Cached Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 2Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 3Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 4Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 5Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 6Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 7Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients 8
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... Medarex, Inc.,(Nasdaq: MEDX ) announced today its financial ... gain of $151.8 million, or $1.19 per share, from Medarex,s,sale ... 2008, Medarex,s,net income for the quarter ended March 31, 2008, ... net income of $110.3 million, or $0.88,per share for the ...
... MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - Innolife Pharma, ... over the previous eight,months regarding the formation of ... in these negotiations where final written terms have ... to the Company,s very first,product acquisition. It should ...
... 12 The American Veterinary,Medical Association (AVMA) has reinforced ... horses and other equines by approving a,new policy on ... by the AVMA Executive Board on April 12, 2008,states ... AVMA opposes the,use of double-deck trailers to transport equines. ...
... The Myanmar Relief Fund,( http://www.MyanmarReliefFund.org ) is a ... the know-how to get aid in and directly ... are treating the,injured, and a myriad of supplies ... is a coalition of private American and Myanmar,citizens ...
... G.,Komen Pittsburgh Race for the Cure(R) are as follows:, 1st Place ... 15:14 Female: Kelly Knickelbein, Pittsburgh, Pa., 19:19, ... Burnett, 16:02 Female: Anna Beck, Washington, Pa., ... Charlie Ban, Pittsburgh, Pa., 16:13 Female: Jessica ...
... Better Care,Better Regulation, WASHINGTON, May 11 ... ManorCare nursing homes in sixteen states,across the nation ... a call to,action from quality care advocates. The ... Managing Director David Rubenstein to demand better,care. In ...
Cached Medicine News:Health News:Medarex Announces 2008 First Quarter Financial Results 2Health News:Medarex Announces 2008 First Quarter Financial Results 3Health News:Medarex Announces 2008 First Quarter Financial Results 4Health News:Medarex Announces 2008 First Quarter Financial Results 5Health News:Medarex Announces 2008 First Quarter Financial Results 6Health News:Medarex Announces 2008 First Quarter Financial Results 7Health News:Medarex Announces 2008 First Quarter Financial Results 8Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2Health News:AVMA Opposes Use of Double-Deck Trailers for Transporting Horses and Other Equines 2Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Advocates Make Mother's Day Push for Quality Care 2
Gentle-Flo® Standard Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
... and Increase Staff Protection With Medline's Sterile Suction ... Fr, 16 Fr and 18 Fr), ,Medline ... the U.S. We manufacture most of our suction ... exceeds our customers' expectations. We manufacture, supply and ...
... are available in two tip ... tip with staggered eyes, and ... types of catheter valve options, ... fingertip control with virtually no ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
Medicine Products: